Evaluation of coverage and compliance of elimination of lymphatic filariasis by mass drug administration campaign in Gulbarga and Yadgiri districts of Karnataka state

Chandrakar, Pradeep Kumar; Rathore, Vikram; Choudhary, Vivek

doi:10.18203/2320-6012.ijrms20150334

Cited by 7 publications

(16 citation statements)

References 6 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18] Different studies gave different explanations for reason for non-compliance [9][10][11][12][13][14][15][16][17] In this study, only 6 persons (1.38%) had mild adverse reactions like nausea, vomiting, mild fever etc after consuming DEC. Consistent results were reported by Jothula KY etal, Prasad V G et al found 1.14%, 1.81% of adverse effects after consuming DEC. (12), (19) This study showed 86.67% households were aware regarding MDA activity from various sources like ASHA, anganwadi workers, health workers, mike announcement etc.…”

Section: Discussionmentioning

confidence: 99%

“…Several other studies across India revealed varied compliance of MDA ranging from 38.8% to 81.15%. [10][11][12][13][14][15] MDA should be implemented in more than 85% of the population in endemic areas and must be sustained for at least five years so that it will interrupt the transmission of filariasis. (3) However in this survey, the effective coverage rate was 77.78% which was lower than the standard target level.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mass Drug Administration Coverage Evaluation for Elimination of Lymphatic Filariasis in Nagpur District of Maharashtra

Jadhao¹

2017

JMSCR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Mass Drug Administration Coverage Evaluation for Elimination of Lymphatic Filariasis in Nagpur District of Maharashtra

Jadhao¹

2017

JMSCR

View full text Add to dashboard Cite

“…In various study conducted in different place in India by Anil, Lata et al, Naveenkumar, Kishore, Amarnath, Muralidhar et al and Nirgude et al also found low compliance rate than recommended level. [8][9][10][14][15][16][17] There is gender wise and age group wise differences in compliance rate in present study. A detailed inquiry into the matter might help us determine the cultural and social factors related age and gender which could have played a role in the compliance rate.…”

Section: Compliance Rate Of Mdamentioning

confidence: 94%

“…In the present study, the coverage rate was 86.5% which is higher as compared to studies by Biradar, Anil, Amarnath, Abhay and lower as compared to studies by Lata and Naveenkumar. 3,[8][9][10]15,17 Coverage rate was highest (87.7%) in 6-14 years age group and lowest (81.9%) in 2-5 years age group. Gender wise coverage was higher (89.94%) in males compared to females ( Table 2).…”

Section: Coverage Rate Of Mdamentioning

confidence: 99%

“…9 The Government of India in 2004 began a nationwide MDA program in all the known lymphatic filariasis endemic districts with the aim of eliminating filariasis as a public health problem by the year 2015. 10 In 2007 India changed its strategy from delivery of DEC alone to delivery of DEC plus albendazole, the number of people treated with combinations has increased steadily. 11 however the reports from field suggested that actual drug consumption was much lower than the reported coverage by district malaria/filarial offices.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of coverage, compliance of mass drug administration and assessment of awareness about lymphatic filariasis in Tikamgarh district of Madhya Pradesh: a cross sectional study

Panika¹,

Sahu²

2019

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: Lymphatic filariasis is the second leading cause of disability worldwide accounting for more than 5 million disability adjusted life years annually. It has been a major public health problem in India which leads to irreversible chronic manifestations which are responsible for considerable economic loss and severe physical disability to the affected individuals. Mass drug administration (MDA) means administration of diethylcarbamazine and albendazole tablets to all people (excluding children <2 years, pregnant women, seriously ill persons) in endemic areas once in a year. The objective of the study was to assess coverage, compliance of MDA and awareness about lymphatic filariasis in Tikamgarh district of Madhya Pradesh.Methods: Cross-sectional study was conducted and total 120 households were surveyed in four randomly selected clusters of Tikamgarh district of Madhya Pradesh.Results: Out of total 743 persons 678 (91.25%) persons were eligible for MDA. Coverage rate was 86.57% and compliance rate was 74.27%. The main reason for non-compliance was not having the concerned disease (55.78%) followed by fear of side effect (22.31%). Only 40.83% among the surveyed families were aware about MDA and only 45.83% respondents had heard about lymphatic filariasis.Conclusions: There is coverage and compliance gap and awareness about the lymphatic filariasis and MDA program is limited. Drug compliance need to be improved and awareness need to be raised. MDA program should not be confined to tablet distribution only and due importance should be given to compliance rate.

show abstract

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

et al. 2021

View full text Add to dashboard Cite

Background Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and albendazole) in India. Methodology/Principal findings This two-armed, open-labelled, block randomised, community study was conducted in LF endemic villages in Yadgir district, Karnataka, India. Consenting participants ≥5 years of age were tested for circulating filarial antigenemia (CFA) and microfilaremia (Mf) before treatment with a single oral dose of IDA or DA. Adverse events (AEs) were monitored actively for two days and passively for five more days. Persons with positive CFA or Mf tests at baseline were retested 12-months post-treatment to assess treatment efficacy. Baseline CFA and Mf—rates were 26.4% and 6.9% in IDA and 24.5% and 6.4% in DA villages respectively. 4758 and 4160 participants received IDA and DA. Most AEs were mild after both treatments; fewer than 0.1% of participants experienced AEs with severity > grade 1. No serious AEs were observed. Fever, headache and dizziness were the most common AEs. AE rates were slightly higher after IDA than DA (8.3% vs. 6.4%, P<0.01). AEs were more frequent in females and Mf-positives after either treatment, but significantly more frequent after IDA (40.5% vs 20.2%, P < 0.001). IDA was more effective for clearing Mf than DA (84% vs. 61.8%, P < 0.001). Geometric mean Mf counts per 60μl in retested Mf-positives decreased by 96.4% from 11.8 after IDA and by 90.0% from 9.5 after DA. Neither treatment was effective for clearing CFA. Conclusions/Significance IDA had an acceptable safety profile and was more effective for clearing Mf than DA. With adequate compliance and medical support to manage AEs, IDA has the potential to accelerate LF elimination in India. Trial registration Clinical Trial Registry of India (CTRI No/2016/10/007399)

show abstract

Evaluation of coverage and compliance of elimination of lymphatic filariasis by mass drug administration campaign in Gulbarga and Yadgiri districts of Karnataka state

Cited by 7 publications

References 6 publications

Mass Drug Administration Coverage Evaluation for Elimination of Lymphatic Filariasis in Nagpur District of Maharashtra

Mass Drug Administration Coverage Evaluation for Elimination of Lymphatic Filariasis in Nagpur District of Maharashtra

Evaluation of coverage, compliance of mass drug administration and assessment of awareness about lymphatic filariasis in Tikamgarh district of Madhya Pradesh: a cross sectional study

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

Contact Info

Product

Resources

About